Free Trial

Iradimed Q4 2022 Earnings Report

Iradimed logo
$60.33 +1.16 (+1.96%)
As of 04:00 PM Eastern

Iradimed EPS Results

Actual EPS
$0.29
Consensus EPS
$0.29
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Iradimed Revenue Results

Actual Revenue
$14.86 million
Expected Revenue
$14.93 million
Beat/Miss
Missed by -$70.00 thousand
YoY Revenue Growth
N/A

Iradimed Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Iradimed Earnings Headlines

IRADIMED Reports Record Revenues for Q4 2024 and Full-Year 2024
DeFi Coin on Verge of Breakout!
The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years.
Iradimed (IRMD) Gets a Buy from Lake Street
Iradimed Reports Growth In Q4, FY Preliminary Revenues
iRadimed reports preliminary Q4 revenue $19.2M-$19.4M
See More Iradimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iradimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iradimed and other key companies, straight to your email.

About Iradimed

Iradimed (NASDAQ:IRMD) Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

View Iradimed Profile

More Earnings Resources from MarketBeat